• DOI:10.1038/s41571-018-0105-0
Corpus ID: 52897928

Therapeutic strategies to target RAS-mutant cancers

@article{Ryan2018TherapeuticST,
  title={Therapeutic strategies to target RAS-mutant cancers},
  author={Meagan B. Ryan and R. Corcoran},
  journal={Nature Reviews Clinical Oncology},
  year={2018},
  volume={15},
  pages={709-720}
}

• Meagan B. Ryan, R. Corcoran
• Published 2018
• Medicine
• Nature Reviews Clinical Oncology

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge is the fact that direct inhibition of RAS proteins has proved difficult, leading researchers to test numerous alternative strategies aimed at exploiting RAS-related vulnerabilities or targeting RAS effectors. In the past few years, we have witnessed renewed efforts to target RAS directly, with several promising… Expand

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed